(August 24, 2016, 12:59 PM EDT) -- ALEXANDRIA, Va. — Assertions that an Aventis Pharma S.A. patent is invalid as obvious under 35 U.S. Code Section 103 were rejected Aug. 23 by the Patent Trial and Appeal Board, which turned away a petition for inter partes review by Mylan Inc. (Mylan Inc. v. Aventis Pharma S.A., No. IPR2016-00627, PTAB)....